T1	Participants 82 111	metastatic colorectal cancer.
T2	Participants 282 495	patients with epidermal growth factor receptor-expressing, metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens.
T3	Participants 817 860	patients with metastatic colorectal cancer.
T4	Participants 993 1023	Patients receiving panitumumab
T5	Participants 1180 1234	patients receiving bevacizumab and chemotherapy alone.
T6	Participants 1728 1756	metastatic colorectal cancer
